Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
CNS Neurol Disord Drug Targets ; 23(9): 1167-1175, 2024.
Article in English | MEDLINE | ID: mdl-38151851

ABSTRACT

AIM: We aimed to investigate the mechanisms involved in the neurotoxic effects of NDGA on differentiated and undifferentiated human neuroblastoma cells (MSN), assessing cell viability, changes in the actin cytoskeleton, cell migration and the expression of the 5-LOX enzyme and the inhibitor of cell cycle progression p21WAF1/CIP1. BACKGROUND: High expression and activity of the lipoxygenase enzyme (LOX) have been detected in several tumors, including neuroblastoma samples, suggesting the use of LOX inhibitors as potential therapy molecules. Among these, the natural compound nordihydroguaiaretic acid (NDGA) has been extensively tested as an antiproliferative drug against diverse types of cancer cells. OBJECTIVE: In this study, we analyzed the toxic effect of NDGA on neuroblastoma cells at a dose that did not affect cell survival when they differentiated to a neuron-like phenotype and the potential mechanisms involved in the anticancer properties. METHODS: We exposed human neuroblastoma cells (MSN) to different concentrations of NDGA before and after a differentiation protocol with retinoic acid and nerve growth factor and analyzed cell viability, cell migration, actin cytoskeleton morphology and the levels of the cell cycle inhibitor p21WAF1/CIP1 and 5-LOX. RESULTS: We found that differentiated human neuroblastoma cells are more resistant to NDGA than undifferentiated cells. The toxic effects of NDGA were accompanied by reduced cell migration, changes in actin cytoskeleton morphology, induction of p21WAF1/CIP1 and decreased levels of the 5-LOX enzyme. CONCLUSION: This study provides new evidence regarding the potential use of NDGA to induce cell death in human neuroblastoma.


Subject(s)
Cell Differentiation , Cell Movement , Cell Survival , Masoprocol , Neuroblastoma , Humans , Neuroblastoma/pathology , Masoprocol/pharmacology , Cell Survival/drug effects , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Arachidonate 5-Lipoxygenase/metabolism , Dose-Response Relationship, Drug , Tretinoin/pharmacology , Lipoxygenase Inhibitors/pharmacology , Antineoplastic Agents/pharmacology
2.
Neurochem Int ; 110: 75-83, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28919254

ABSTRACT

The high consumption of saturated lipids has been largely associated with the increasing prevalence of metabolic diseases. In particular, saturated fatty acids such as palmitic acid (PA) have been implicated in the development of insulin resistance in peripheral tissues. However, how neurons develop insulin resistance in response to lipid overload is not fully understood. Here, we used cultured rat cortical neurons and differentiated human neuroblastoma cells to demonstrate that PA blocks insulin-induced metabolic activation, inhibits the activation of the insulin/PI3K/Akt pathway and activates mTOR kinase downstream of Akt. Despite the fact that fatty acids are not normally used as a significant source of fuel by neural cells, we also found that short-term neuronal exposure to PA reduces the NAD+/NADH ratio, indicating that PA modifies the neuronal energy balance. Finally, inhibiting mitochondrial ROS production with mitoTEMPO prevented the deleterious effect of PA on insulin signaling. This work provides novel evidence of the mechanisms behind saturated fatty acid-induced insulin resistance and its metabolic consequences on neuronal cells.


Subject(s)
Insulin/metabolism , Palmitic Acid/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Reactive Oxygen Species/metabolism , TOR Serine-Threonine Kinases/metabolism , Animals , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Line, Tumor , Cells, Cultured , Energy Metabolism/drug effects , Energy Metabolism/physiology , Humans , Insulin Antagonists/pharmacology , Mitochondria/drug effects , Mitochondria/metabolism , Neuroblastoma/metabolism , Phosphoinositide-3 Kinase Inhibitors , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Rats , Signal Transduction
3.
Cell Mol Neurobiol ; 37(7): 1311-1318, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28124209

ABSTRACT

Amyloid-ß protein (Aß) neurotoxicity occurs along with the reorganization of the actin-cytoskeleton through the activation of the Rho GTPase pathway. In addition to the classical mode of action of the non-steroidal anti-inflammatory drugs (NSAIDs), indomethacin, and ibuprofen have Rho-inhibiting effects. In order to evaluate the role of the Rho GTPase pathway on Aß-induced neuronal death and on neuronal morphological modifications in the actin cytoskeleton, we explored the role of NSAIDS in human-differentiated neuroblastoma cells exposed to Aß. We found that Aß induced neurite retraction and promoted the formation of different actin-dependent structures such as stress fibers, filopodia, lamellipodia, and ruffles. In the presence of Aß, both NSAIDs prevented neurite collapse and formation of stress fibers without affecting the formation of filopodia and lamellipodia. Similar results were obtained when the downstream effector, Rho kinase inhibitor Y27632, was applied in the presence of Aß. These results demonstrate the potential benefits of the Rho-inhibiting NSAIDs in reducing Aß-induced effects on neuronal structural alterations.


Subject(s)
Actins/metabolism , Amyloid beta-Peptides/toxicity , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cytoskeleton/enzymology , Peptide Fragments/toxicity , Signal Transduction/physiology , rho-Associated Kinases/physiology , Cell Line, Tumor , Cytoskeleton/drug effects , Cytoskeleton/pathology , Enzyme Inhibitors/pharmacology , Humans , Signal Transduction/drug effects , rho-Associated Kinases/antagonists & inhibitors
4.
Neurochem Res ; 37(9): 1879-85, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22638775

ABSTRACT

Synaptic loss is a major neuropathological correlate of memory decline as a result of Alzheimer's disease (AD). This phenomenon appears to be aggravated by soluble amyloid-ß (Aß) oligomers causing presynaptic terminals to be particularly vulnerable to damage. Furthermore, insulin is known to participate in synaptic plasticity through the activation of the insulin receptor (IR) and the PI3K signaling pathway, while low concentrations of soluble Aß and Aß oligomers aberrantly modulate IR function in cultured neurons. To further examine how Aß and insulin interact in the pathology of AD, the present work analyzes the effect of insulin and Aß in the activation of the IR/PI3K pathway in synaptosomes. We found that insulin increased mitochondrial activity and IR/Akt phosphorylation in synaptosomes taken from both hippocampus and cortex. Also, pretreatment with Aß antagonized insulin's effect on hippocampal synaptosomes, but not vice versa. These results show that Aß can reduce responsiveness to insulin. Combined with evidence that insulin desensitization can increase the risk of developing AD, our results suggest that the initial mechanism that impairs synaptic maintenance in AD might start with Aß changes in insulin sensitivity.


Subject(s)
Amyloid beta-Peptides/pharmacology , Insulin/physiology , Presynaptic Terminals/drug effects , Signal Transduction/drug effects , Animals , Blotting, Western , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Hypoglycemic Agents/pharmacology , In Vitro Techniques , Insulin/pharmacology , Insulin Receptor Substrate Proteins/metabolism , Insulin Resistance/physiology , Male , Mitochondria/drug effects , Mitochondria/metabolism , Oncogene Protein v-akt/physiology , Oxidation-Reduction , Phosphatidylinositol 3-Kinases/metabolism , Rats , Receptor, Insulin/physiology , Synapses/drug effects , Synapses/pathology , Synaptosomes/drug effects , Synaptosomes/metabolism
5.
Neurochem Res ; 33(8): 1509-17, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18288607

ABSTRACT

Alterations in brain cholesterol concentration and metabolism seem to be involved in Alzheimer's disease (AD). In fact, several experimental studies have reported that modification of cholesterol content can influence the expression of the amyloid precursor protein (APP) and amyloid beta peptide (Abeta) production. However, it remains to be determined if changes in neuronal cholesterol content may influence the toxicity of Abeta peptides and the mechanism involved. Aged mice, AD patients and neurons exposed to Abeta, show a significant increase in membrane-associated oxidative stress. Since Abeta is able to promote oxidative stress directly by catalytically producing H(2)O(2) from cholesterol, the present work analyzed the effect of high cholesterol incorporated into human neuroblastoma cells in Abeta-mediated neurotoxicity and the role of reactive oxygen species (ROS) generation. Neuronal viability was studied also in the presence of 24S-hydroxycholesterol, the main cholesterol metabolite in brain, as well as the potential protective role of the lipophilic statin, lovastatin.


Subject(s)
Amyloid beta-Peptides , Cholesterol/metabolism , Neuroblastoma/metabolism , Oxidative Stress , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/toxicity , Animals , Anticholesteremic Agents/metabolism , Anticholesteremic Agents/pharmacology , Cell Line, Tumor/drug effects , Cell Line, Tumor/metabolism , Cell Survival , Filipin/metabolism , Humans , Lipid Peroxidation , Lovastatin/metabolism , Lovastatin/pharmacology , Mice , Reactive Oxygen Species/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL